Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lago

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Digestive Diseases and Sciences|January 9, 2009
Inflammatory bowel disease: a patient's and caregiver's perspectiveF Magro, F Portela, P Lago, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution StudyF Magro, S Lopes, M Silva, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2010
Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approachL F Azevedo, F Magro, F Portela, et al.
United European Gastroenterology Journal|December 9, 2024
Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment OutcomesD Magalhaes, M Santiago, M Patita, et al.
Trials|July 3, 2024
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial)Giovanni Vento, Angela Paladini, C Aurilia, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Digestive Diseases and Sciences|January 9, 2009
Inflammatory bowel disease: a patient's and caregiver's perspectiveF Magro, F Portela, P Lago, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution StudyF Magro, S Lopes, M Silva, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2010
Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approachL F Azevedo, F Magro, F Portela, et al.
United European Gastroenterology Journal|December 9, 2024
Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment OutcomesD Magalhaes, M Santiago, M Patita, et al.
Trials|July 3, 2024
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial)Giovanni Vento, Angela Paladini, C Aurilia, et al.
Pageof 6